You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CSCC of Extremity

Showing 1 - 25 of 2,392
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Cutaneous Squamous Cell Carcinoma Trial in Australia, Germany, United States (Cemiplimab)

Active, not recruiting
  • Cutaneous Squamous Cell Carcinoma
  • Palo Alto, California
  • +21 more
Apr 5, 2022

Advanced Cutaneous Squamous Cell Carcinoma Trial in Worldwide (cemiplimab)

Active, not recruiting
  • Advanced Cutaneous Squamous Cell Carcinoma
  • Phoenix, Arizona
  • +77 more
Jan 4, 2023

CemiplimAb Survivorship Epidemiology

Recruiting
  • Cutaneous Squamous Cell Carcinoma
  • Basal Cell Carcinoma
  • Huntsville, Alabama
  • +52 more
Dec 14, 2022

Cutaneous Squamous Cell Carcinoma Staging Study

Not yet recruiting
  • Cutaneous Squamous Cell Carcinoma
  • This is not an interventional study
  • (no location specified)
Jan 20, 2023

Basal Cell Carcinoma, Cutaneous Squamous Cell Carcinoma Trial

Not yet recruiting
  • Basal Cell Carcinoma
  • Cutaneous Squamous Cell Carcinoma
    • (no location specified)
    Feb 14, 2023

    Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma Trial in United States (Cemiplimab)

    Recruiting
    • Cutaneous Squamous Cell Carcinoma
    • Redwood City, California
    • +8 more
    Mar 28, 2022

    Advanced Cutaneous Squamous Cell Carcinoma Trial in Guangzhou (IBI318)

    Active, not recruiting
    • Advanced Cutaneous Squamous Cell Carcinoma
    • Guangzhou, China
      Sun Yat-sen University Cancer Center
    Oct 10, 2022

    Squamous Cell Carcinoma, RP1 Trial (RP1)

    Not yet recruiting
    • Squamous Cell Carcinoma
    • RP1
    • (no location specified)
    May 4, 2023

    Cutaneous Squamous Cell Carcinoma Trial in Worldwide (Cemiplimab, Placebo)

    Recruiting
    • Cutaneous Squamous Cell Carcinoma
    • Gilbert, Arizona
    • +143 more
    Dec 1, 2022

    Cutaneous Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma of the Head and Neck, Tumors Trial in Melbourne

    Not yet recruiting
    • Cutaneous Squamous Cell Carcinoma
    • +3 more
    • Melbourne, Victoria, Australia
      Peter MacCallum Cancer Centre
    May 17, 2023

    Squamous Cell Carcinoma Trial in Tampa (Afatinib 40 MG)

    Recruiting
    • Squamous Cell Carcinoma
    • Afatinib 40 MG
    • Tampa, Florida
      Moffitt Cancer Center
    Dec 30, 2022

    Squamous Cell Carcinoma of the Skin Trial in Zhengzhou (Camrelizumab)

    Not yet recruiting
    • Squamous Cell Carcinoma of the Skin
    • Zhengzhou, Henan, China
      Department of Bone and Soft Tissue ,Henan Cancer Hospital
    Aug 3, 2022

    Basal Cell Carcinoma, Cutaneous Squamous Cell Carcinoma Trial in Lausanne (FLASH RT, Conventional RT)

    Not yet recruiting
    • Basal Cell Carcinoma
    • Cutaneous Squamous Cell Carcinoma
    • FLASH RT
    • Conventional RT
    • Lausanne, Vaud, Switzerland
      Centre Hospitalier Universitaire Vaudois (CHUV)
    Feb 13, 2023

    Hepatocellular Carcinoma, Liver Metastases, Cutaneous or Subcutaneous Lymph Node Trial in Worldwide (Talimogene Laherparepvec,

    Active, not recruiting
    Has Results
    • Hepatocellular Carcinoma
    • +3 more
    • Scottsdale, Arizona
    • +31 more
    Dec 7, 2022

    Cutaneous Squamous Cell Carcinoma, Sentinel Lymph Node Trial in Montreal (Sentinel Lymph Node Biopsy)

    Recruiting
    • Cutaneous Squamous Cell Carcinoma
    • Sentinel Lymph Node
    • Sentinel Lymph Node Biopsy
    • Montreal, Quebec, Canada
      Jewish General Hospital
    Apr 2, 2022

    Cutaneous Squamous Cell Carcinoma Trial in Guangzhou (HLX07)

    Recruiting
    • Cutaneous Squamous Cell Carcinoma
    • Guangzhou, Guangdong, China
      Nanfang Hospital
    Jun 15, 2022

    Cutaneous Squamous Cell Carcinoma, Skin Cancer, Squamous Cell Carcinoma Trial in United States (Cemiplimab, Radiotherapy)

    Recruiting
    • Cutaneous Squamous Cell Carcinoma
    • +6 more
    • Aurora, Colorado
    • +11 more
    Oct 12, 2022

    Squamous Cell Carcinoma Trial (MK-3475A)

    Not yet recruiting
    • Squamous Cell Carcinoma
    • MK-3475A
    • (no location specified)
    Sep 11, 2023

    Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma, Advanced Squamous Cell Carcinoma Trial in Miami (Cemiplimab-Rwlc,

    Not yet recruiting
    • Cutaneous Squamous Cell Carcinoma
    • +2 more
    • Miami, Florida
      Miami Cancer Institute at Baptist Health, Inc.
    Feb 6, 2023

    Cutaneous Squamous Cell Carcinoma, Advanced Cancer Trial in Boston (Cemiplimab, Everolimus, Sirolimus)

    Recruiting
    • Cutaneous Squamous Cell Carcinoma
    • Advanced Cancer
    • Boston, Massachusetts
      Dana Farber Cancer Institute
    Jan 19, 2023

    Carcinoma, Squamous Cell Trial in Worldwide (Pembrolizumab 400 mg, Placebo)

    Recruiting
    • Carcinoma, Squamous Cell
    • Pembrolizumab 400 mg
    • Placebo
    • Mobile, Alabama
    • +170 more
    Jan 19, 2023

    Squamous Cell Carcinoma, Skin Cancer, Keratoacanthoma Trial in Scottsdale, Tucson (Injection of TVEC into target lesions - week

    Recruiting
    • Squamous Cell Carcinoma
    • +5 more
    • Injection of TVEC into target lesions - week 1-2
    • +3 more
    • Scottsdale, Arizona
    • +1 more
    Apr 6, 2022

    Head and Neck Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Head Neck Cancer Trial in United States (Lenvatinib

    Completed
    • Head and Neck Squamous Cell Carcinoma
    • +3 more
    • Basking Ridge, New Jersey
    • +6 more
    Oct 13, 2022

    Solid Tumor, Cutaneous Squamous Cell Carcinoma, Endometrial Cancer Trial (favezelimab/pembrolizumab, pembrolizumab, lenvatinib)

    Not yet recruiting
    • Solid Tumor
    • +2 more
    • favezelimab/pembrolizumab
    • +2 more
    • (no location specified)
    Sep 7, 2023

    Cutaneous Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma of the Head and Neck Trial in Tucson, Tampa

    Terminated
    Has Results
    • Cutaneous Squamous Cell Carcinoma
    • Cutaneous Squamous Cell Carcinoma of the Head and Neck
    • Tucson, Arizona
    • +1 more
    Nov 2, 2022